Elixirgen Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Rollover Study From EXG-US-01
Phase 1
- Conditions
- Telomere Biology Disorders With Bone Marrow Failure
- Interventions
- Biological: EXG34217
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Elixirgen Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05868499
- Locations
- 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Elixirgen Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04211714
- Locations
- 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath